在已知的冠状动脉疾病患者中,基于指南的他类药物使用和复发事件的性别差异
Agnes Koczo1, Jianhui Zhu1, Floyd Thoma1
1University of Pittsburgh Medical Center, Heart and Vascular Institute, Pittsburgh, Pennsylvania, USA.
American journal of preventive cardiology
|October 6, 2025
概括
患有动脉样硬化心血管疾病 (ASCVD) 的妇女接受的指导方针指导的他强度 (GDSI) 较低,并且具有更高的ASCVD事件风险. 针对性别的干预措施对于公平的ASCVD预防至关重要.
科学领域:
- 心脏病学 心脏病学
- 预防医学 预防医学
- 健康 公平 卫生 公平
背景情况:
- 目前的指导方针主张用于动脉样硬化心血管疾病 (ASCVD) 的高强度他类药物.
- 在指导方针指导的他强度 (GDSI) 和ASCVD结果中可能存在基于性别的差异.
- 了解这些差异对于优化心血管保健至关重要.
研究的目的:
- 研究已确定的冠状动脉疾病患者在GDSI利用中的基于性别的差异.
- 评估GDSI和复发性ASCVD事件之间的关联,按性别分层.
- 发现女性心血管疾病预防策略中的潜在缺口.
主要方法:
- 一项回顾性队列研究分析了2010年至2022年期间45949名冠状动脉疾病患者的电子病历.
- 达丁类药物的使用被分为GDSI,
- 复发性心肌梗塞 (MI),中风/TIA和全因死亡率使用考克斯回归来评估,按性别分层.
主要成果:
- 妇女占该队列的31%,并呈现出更多的伴随性疾病,如糖尿病.
- 妇女接受GDSI的可能性低于男性 (61.6%vs. 65.8%),并且达到LDL-C<70 mg/dL (41%vs. 49%).
- 尽管GDSI降低了两性事件率,但与男性相比,GDSI的女性患心脏病,中风和死亡率的风险更高.
结论:
- 患有冠状动脉疾病的女性不太可能接受最佳的他类药物治疗,并面临更高的心血管事件的风险.
- 这凸显了需要针对性别的具体策略,以改善GDSI的实施,并实现指南推的脂质目标.
- 解决这些差异对于公平有效地预防女性ASCVD至关重要.
关键词:
这是一个ASCVD.冠状动脉疾病是一种冠状动脉疾病.性差异性差异性差异性差异性差异性差异性差异性差异性差异性差异性差异性差异性差异性差异性差异性差异性差异性差异性差异性差异性差异性差异性差异性差异性差异性差异性差异性差异性差异性差异性差异性差异性差异性差异性差异性差异类他类药物是一种药物.女人的心血管健康更多相关视频
06:16Signal Acquisition, Score Interpretation, and Economics of a Non-Invasive Point-of-Care Test for Coronary Artery Disease
Published on: August 9, 2024
809
06:55Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
Published on: January 8, 2020
15.0K
相关概念视频
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
1.3K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.3K
01:26Coronary Artery Disease IV: Preventive Measures
589
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
589
01:26Atherosclerosis III: Management
319
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
319
01:27Coronary Artery Disease V: Interprofessional Care
215
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
215
01:30Acute Coronary Syndrome III: Diagnostic Studies
213
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
213
01:26Angina IV: Management
236
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
236